MedTrace Logo

Drug-drug Interaction Study Between UIC201601 and UIC201602

NCT05190133 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-01-13

No results posted yet for this study

Summary

An open-label, multiple-dosing, two-arms, one-sequence study to evaluate the safety and pharmacokinetics after co-administration of UIC201601 and UIC201602 in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

UIC201602 and co-administration of UIC201601 and UIC201602

* UIC201602 4 Cap/day for 14 days * Wash out 21 days * UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days

DRUG

UIC201601 and co-administration of UIC201601 and UIC201602

* UIC201601 4 Tab/day for 7 days * Wash out 14 days * UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days

Sponsors & Collaborators

  • Korea United Pharm. Inc.

    lead INDUSTRY

Principal Investigators

  • Janghee Hong, M.D.,Ph.D. · Chungnam National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-28
Primary Completion
2016-08-17
Completion
2016-08-17

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05190133 on ClinicalTrials.gov